Anti-Atezolizumab Antibodies

Antibodies for bioanalysis and drug monitoring of atezolizumab and biosimilars

Develop highly selective and sensitive pharmacokinetic (PK) and anti-drug antibody (ADA) assays for the monoclonal antibody atezolizumab (Tecentriq) using our range of ready-made antibodies.

  • Recombinant antibodies specific to atezolizumab
  • TrailBlazer Antibodies enabling site-directed conjugation and format switching
  • Fully human format for surrogate positive control or calibrator
  • Sequence-defined, well characterized reagents with secure supply
  • Stringent quality control for batch-to-batch consistency

Table 1. Antibodies Specific to Atezolizumab

Specificity
Binding Type

Catalog Number

Clone

Format

Affinity* KD, nM

Assay Recommendation

Product Details

Atezolizumab

Inhibitory

Type 1

HCA380

AbD41002_hIgG1

Human IgG1

16

ADA control

Order HCA380

HCA381

AbD40992ia_hIgG1

Human IgG1

1.4

PK bridging ELISA

ADA control

Order HCA381

HCA382

AbD40638ia_hIgG1

Human IgG1

0.4

ADA control

Order HCA382

TZA011

AbD40638ad

Fab-F-Spy2-H1

0.4

PK bridging ELISA

Order TZA011

Anti-Atezolizumab Inhibitory Antibodies (Type 1)

Type 1 anti-atezolizumab antibodies inhibit the binding of the monoclonal antibody drug atezolizumab to its target, programmed cell death ligand 1 (PD-L1). They are ideal for development of a PK bridging ELISA to measure free drug. Four clones are available in fully human IgG1 format for use as a surrogate positive control or reference standard in an ADA assay.

TrailBlazer Antibody, clone AbD40638ad (TZA011) has a SpyTag2 incorporated at the C-terminus of the antibody heavy chain. In a fast reaction that simply requires mixing at room temperature, these antibodies can form a covalent isopeptide bond to a SpyCatcher reagent, enabling site-directed conjugation or fast conversion to a bivalent Fab or a full-length Ig-like format within an hour.

ELISA Protocols to Get You Started

PK Bridging ELISA 

PK bridging ELISA free drug: TZA011 and HCA381

Fig. 1. Atezolizumab PK bridging ELISA using antibodies TZA011 and HCA381.

Fig. 1. Atezolizumab PK bridging ELISA using antibodies TZA011 and HCA381.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.

 ADA Bridging ELISA

ADA bridging ELISA: HCA380, HCA381, or HCA382 fully human IgG1 as surrogate positive control or calibrator

Fig. 2. Alemtuzumab ADA bridging ELISA using antibody HCA199.

Fig. 2. Atezolizumab ADA bridging ELISA using antibody HCA380, HCA381, or HCA382.

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

Resources

SpyTag and SpyCatcher products

TrailBlazer Antibodies

Anti-idiotypic antibodies, their binding types and properties

Anti-biotherapeutic antibody quality control and characterization

Custom anti-idiotypic antibody generation service

Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.